Giuditta Illuzzi

1.2k total citations
20 papers, 585 citations indexed

About

Giuditta Illuzzi is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Giuditta Illuzzi has authored 20 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 14 papers in Oncology and 4 papers in Cell Biology. Recurrent topics in Giuditta Illuzzi's work include PARP inhibition in cancer therapy (14 papers), DNA Repair Mechanisms (12 papers) and CRISPR and Genetic Engineering (5 papers). Giuditta Illuzzi is often cited by papers focused on PARP inhibition in cancer therapy (14 papers), DNA Repair Mechanisms (12 papers) and CRISPR and Genetic Engineering (5 papers). Giuditta Illuzzi collaborates with scholars based in United Kingdom, Italy and France. Giuditta Illuzzi's co-authors include Françoise Dantzer, Valérie Schreiber, Sandro Sonnino, Vanna Chigorno, Massimo Aureli, Alessandro Prinetti, Simona Prioni, Jean‐Christophe Amé, Paul W.G. Wijnhoven and Antonio Ramos‐Montoya and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Cancer Research.

In The Last Decade

Giuditta Illuzzi

19 papers receiving 580 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giuditta Illuzzi United Kingdom	12	467	310	100	71	62	20	585
Jo Waaler Norway	17	981 2.1×	303 1.0×	156 1.6×	108 1.5×	32 0.5×	22	1.2k
Stephany Veuger United Kingdom	9	473 1.0×	324 1.0×	21 0.2×	48 0.7×	30 0.5×	16	609
Hiroshi Koutoku Japan	12	367 0.8×	162 0.5×	48 0.5×	54 0.8×	21 0.3×	22	527
You-Wei Zhang United States	9	784 1.7×	299 1.0×	164 1.6×	39 0.5×	23 0.4×	9	838
Mika Aoyagi-Scharber United States	7	293 0.6×	314 1.0×	20 0.2×	55 0.8×	30 0.5×	10	481
Maria Neve Cervellera Italy	9	260 0.6×	306 1.0×	22 0.2×	166 2.3×	34 0.5×	9	532
Friederike C. von Lintig United States	11	451 1.0×	198 0.6×	60 0.6×	50 0.7×	59 1.0×	13	636
Rebecca Gilley United Kingdom	12	564 1.2×	176 0.6×	95 0.9×	86 1.2×	23 0.4×	14	723
Maddison Rose Australia	7	356 0.8×	358 1.2×	21 0.2×	52 0.7×	11 0.2×	7	597

Countries citing papers authored by Giuditta Illuzzi

Since Specialization

Citations

This map shows the geographic impact of Giuditta Illuzzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuditta Illuzzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuditta Illuzzi more than expected).

Fields of papers citing papers by Giuditta Illuzzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giuditta Illuzzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuditta Illuzzi. The network helps show where Giuditta Illuzzi may publish in the future.

Co-authorship network of co-authors of Giuditta Illuzzi

This figure shows the co-authorship network connecting the top 25 collaborators of Giuditta Illuzzi. A scholar is included among the top collaborators of Giuditta Illuzzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giuditta Illuzzi. Giuditta Illuzzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Illuzzi, Giuditta, Alessandro Galbiati, Anna D. Staniszewska, et al.. (2025). Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair. NAR Cancer. 7(4). zcaf035–zcaf035.

Hollis, Robert L., Neil O. Carragher, Mark R. Albertella, et al.. (2024). 350 (PB338): Structural variants of BRCA1/2 represent a novel biomarker of homologous recombination deficiency in multiple tumour types. European Journal of Cancer. 211. 114863–114863. 1 indexed citations

Albertella, Mark R., Paul W.G. Wijnhoven, Annie Albert Demin, et al.. (2023). Abstract B058: Combination of the PARP1-selective inhibitor AZD5305 with the ATR inhibitor ceralasertib for the treatment of PARPi-resistant cancer. Molecular Cancer Therapeutics. 22(12_Supplement). B058–B058. 1 indexed citations

Moorthy, Ganesh, Veronika Voronova, César Pichardo‐Almarza, et al.. (2023). Abstract 2794: A Quantitative Systems Pharmacology (QSP) model to characterize dose-dependent antitumor activity of AZD5305, PARP1 selective inhibitor, across multiple xenograft models. Cancer Research. 83(7_Supplement). 2794–2794. 1 indexed citations

Galbiati, Alessandro, Joshua Armenia, Giuditta Illuzzi, et al.. (2022). Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition. Cancer Research Communications. 2(10). 1244–1254. 11 indexed citations

Staniszewska, Anna D., Domenic Pilger, Giuditta Illuzzi, et al.. (2022). DDDR-01. AZD9574 IS A NOVEL, BRAIN PENETRANT PARP-1 SELECTIVE INHIBITOR WITH ACTIVITY IN AN INTRACRANIAL XENOGRAFT MODEL OF TRIPLE NEGATIVE BREAST CARCINOMA WITH HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY. Neuro-Oncology. 24(Supplement_7). vii98–vii98. 2 indexed citations

Wijnhoven, Paul W.G., Antonio Ramos‐Montoya, Zena Wilson, et al.. (2020). Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 39(25). 4869–4883. 126 indexed citations

Illuzzi, Giuditta, Michael Churchman, Robert L. Hollis, et al.. (2020). Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells. Cancers. 12(6). 1503–1503. 22 indexed citations

Illuzzi, Giuditta, Mark J. O’Connor, & Elisabetta Leo. (2019). Abstract 2077: A novel assay for PARP-DNA trapping provides insights into the mechanism of action (MoA) of clinical PARP inhibitors (PARPi). Cancer Research. 79(13_Supplement). 2077–2077. 6 indexed citations

10.

Rodríguez-Vargas, José Manuel, María Isabel Rodríguez, Jara Majuelos‐Melguizo, et al.. (2016). Autophagy requires poly(adp-ribosyl)ation-dependent AMPK nuclear export. Cell Death and Differentiation. 23(12). 2007–2018. 46 indexed citations

11.

Illuzzi, Giuditta, et al.. (2016). PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency. Cancer Cell International. 16(1). 53–53. 17 indexed citations

12.

Schreiber, Valérie, Giuditta Illuzzi, Éléa Héberlé, & Françoise Dantzer. (2015). De la découverte du poly(ADP-ribose) aux inhibiteurs PARP en thérapie du cancer. Bulletin du Cancer. 102(10). 863–873. 10 indexed citations

13.

Illuzzi, Giuditta, Elise Fouquerel, Jean‐Christophe Amé, et al.. (2014). PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress. Nucleic Acids Research. 42(12). 7776–7792. 58 indexed citations

14.

Beck, Carole, Christian Boehler, Josée Guirouilh‐Barbat, et al.. (2014). PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways. Nucleic Acids Research. 42(9). 5616–5632. 82 indexed citations

15.

Prinetti, Alessandro, Ting Cao, Giuditta Illuzzi, et al.. (2011). A Glycosphingolipid/Caveolin-1 Signaling Complex Inhibits Motility of Human Ovarian Carcinoma Cells. Journal of Biological Chemistry. 286(47). 40900–40910. 29 indexed citations

16.

Prinetti, Alessandro, Simona Prioni, Nicoletta Loberto, et al.. (2011). Aberrant Glycosphingolipid Expression and Membrane Organization in Tumor Cells: Consequences on Tumor–Host Interactions. Advances in experimental medicine and biology. 705. 643–667. 11 indexed citations

17.

Illuzzi, Giuditta, Caterina Bernacchioni, Massimo Aureli, et al.. (2010). Sphingosine Kinase Mediates Resistance to the Synthetic Retinoid N-(4-Hydroxyphenyl)retinamide in Human Ovarian Cancer Cells. Journal of Biological Chemistry. 285(24). 18594–18602. 42 indexed citations

18.

Valsecchi, Manuela, Massimo Aureli, Laura Mauri, et al.. (2010). Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids. Journal of Lipid Research. 51(7). 1832–1840. 23 indexed citations

19.

Aureli, Massimo, Giuditta Illuzzi, Nicoletta Loberto, et al.. (2009). Activity of plasma membrane β‐galactosidase and β‐glucosidase. FEBS Letters. 583(15). 2469–2473. 52 indexed citations

20.

Prinetti, Alessandro, Massimo Aureli, Giuditta Illuzzi, et al.. (2009). GM3 synthase overexpression results in reduced cell motility and in caveolin-1 upregulation in human ovarian carcinoma cells. Glycobiology. 20(1). 62–77. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact